Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270526 | PMC |
| http://dx.doi.org/10.1080/15384101.2016.1235845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of proliferation, migration and invasion of RM-1 cells by roemerine: Insights from in vitro and in vivo studies.
Tissue Cell
December 2024
Department of Urology, Women and Children's Hospital, Qingdao University, Qingdao, Shandong Province 266109, China. Electronic address:
Prostate cancer is the second leading cause of cancer-related among men globally, with a rising incidence rate, particularly in developing countries. This highlights the urgent need to identify novel therapeutic agents. Roemerine, a naturally abundant alkaloid, has demonstrated antibacterial and antitumor properties, suggesting its potential utility in prostate cancer treatment.
View Article and Find Full Text PDFCasual detection of an abdominal aortic aneurysm thanks to a trainee-made ultrasound with two subsequent "domino" diagnoses: case report and insights on the role of ultrasound courses.
J Ultrasound
December 2024
Geriatrics Unit, Garibaldi-Nesima Hospital, Catania, Italy.
Early detection of abdominal aortic aneurysm (AAA) is crucial as untreated lesions can be life-threatening. We describe the case of a fortuitous ultrasound (US) detection of AAA by a trainee which allowed two subsequent "domino" diagnoses. A 69 y.
View Article and Find Full Text PDFIdentifying therapeutic target for prostate cancer: exploring Diosmetin as a CYP inhibitor.
Discov Oncol
December 2024
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, 80203, Jeddah, Saudi Arabia.
Prostate cancer is a prevalent and highly heterogeneous malignancy that affects men globally. Despite the availability of various treatment targets, Cytochrome P450 (CYP) enzymes have gained significant attention due to their crucial role in metabolizing both endogenous and exogenous compounds. This study explores Diosmetin as a potential CYP antagonist for treating prostate cancer.
View Article and Find Full Text PDFA TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.
Oncogene
December 2024
Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Recent studies suggest that glucocorticoid receptor (GR) activation can cause enzalutamide resistance in advanced prostate cancer (PCa) via functional bypass of androgen receptor (AR) signaling. However, the specific molecular mechanism(s) driving this process remain unknown. We have previously reported that the transcription factor TBX2 is over-expressed in castrate-resistant prostate cancer (CRPC).
View Article and Find Full Text PDFRole of LEDGF/p75 (PSIP1) in oncogenesis. Insights in molecular mechanism and therapeutic potential.
Biochim Biophys Acta Rev Cancer
December 2024
Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address:
Aberrant gene expression due to dysfunction in proteins involved in transcriptional regulation is a hallmark of tumor development. Indeed, targeting transcriptional regulators represents an emerging approach in cancer therapeutics. Lens epithelium-derived growth factor (LEDGF/p75, PSIP1) is a co-transcriptional activator that tethers several proteins to the chromatin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!